AT
TEVA icon

Argent Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Argent Trust’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,528
Closed -$221K – 209
2017
Q3 		$221K Sell
12,528
-18,300
-59% -$412K 0.06% 200
2017
Q2 		$1.02M Sell
30,828
-3,118
-9% -$96.5K 0.29% 94
2017
Q1 		$1.09M Buy
33,946
+5,377
+19% +$184K 0.31% 85
2016
Q4 		$1.03M Buy
28,569
+11,929
+72% +$476K 0.3% 84
2016
Q3 		$766K Buy
16,640
+2,660
+19% +$139K 0.23% 101
2016
Q2 		$702K Hold
13,980
– – 0.22% 103
2016
Q1 		$748K Buy
13,980
+40
+0.3% +$2.35K 0.24% 97
2015
Q4 		$915K Buy
+13,940
New +$861K 0.3% 87

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Argent Trust's TEVA Position: Q4 2017 in Review

Argent Trust sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 12,528 shares — an estimated $221K sold.

Argent Trust first reported a position in TEVA in Q4 2015 and held it in 8 quarters. The position peaked at $1.09M in Q1 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Argent Trust reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Argent Trust sold 12,528 Teva Pharmaceuticals shares in Q4 2017, an estimated $221K.
  • Argent Trust first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Argent Trust's Teva Pharmaceuticals position peaked at $1.09M in Q1 2017.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Argent Trust's 13F filing for Q4 2017, filed 15 Feb 2018.